PeiLinMD

Hematopathology, Anatomic Pathology, Clinical Pathology

professor

Dr. Lin is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas M D Anderson Cancer CenterFellowship, Hematopathology, 1999 - 2000
Yale-New Haven Medical CenterResidency, Pathology-Anatomic and Clinical, 1995 - 1999
Nanjing Medical UniversityClass of 1982

PubMed

1 citations
The Spectrum of B-cell and Plasma Cell Proliferations in Nodal T Follicular Helper Cell Lymphomas.
Roman Segura-Rivera, Nicholas Joseph Dcunha, Yiannis Petros Dimopoulos, Aniruddha Mundhada, Tania P Sainz
The American Journal of Surgical Pathology. 2025-03-01
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets.
Luz Yurany Moreno Rueda, Hua Wang, Keiko Akagi, Minghao Dang, Amishi Vora
Cell Reports. Medicine. 2025-02-18
Flow cytometric immunophenotypic features of acute myeloid leukemia with mast cell differentiation.
Jie Xu, Do Hwan Kim, Wei Wang, Shaoying Li, Pei Lin
American Journal of Clinical Pathology. 2025-02-12

Journal Articles

Original Contribution Utility of JAK2 V617F Allelic Burden in Distinguishing Chronic Myelomonocytic Leukemia from Primary Myelofibrosis with Monocytosis☆
Shaoying Li, L Jeffrey Medeiros, Pei Lin, Srdan Verstovsek, ScienceDirect
Original Contribution IgM Plasma Cell Myeloma in the Era of Novel Therapy: A Clinicopathologic Study of 17 Cases☆
Shaoying Li, Pei Lin, L Jeffrey Medeiros, Guilin Tang, ScienceDirect

Abstracts/Posters

A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
A Multicenter Phase II Single Arm Trial of Isatuximab in Patients with High Risk Smoldering Multiple Myeloma (HRSMM)
Pei Lin, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019